ReviewCurrent hematologic malignancy reports2006
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.
Review in Current hematologic malignancy reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Magnetic Nanoparticles PCR Enzyme-Linked Gene Assay for Quantitative Detection of BCR/ABL Fusion Gene in Chronic Myelogenous Leukemia.Journal of clinical laboratory analysis · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sensitive detection of minimal residual disease by the polymerase chain reaction (PCR) has revolutionized our ability to follow treatment response and predict relapse. Examples of how the detection of minimal residual disease can drive clinical research are best found in chronic myeloid leukemia (CML). The use of PCR to detect the BCR-ABL chimeric transcript in CML has been found to predict relapse in the transplant setting, and more recently, has been found in trials of imatinib to be a strong measure in predicting progression-free survival. In addition, clinical trials are now under way using the quantitative assessment of BCR-ABL as a surrogate outcome marker, potentially reducing the time and cost of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.